| Human epidermal growth factor receptor 2 (HER2)–specific chimeric antigen receptor–modified T cells for the immunotherapy of HER2-positive sarcoma N Ahmed, VS Brawley, M Hegde, C Robertson, A Ghazi, C Gerken, E Liu, ... Journal of clinical oncology 33 (15), 1688, 2015 | 1011 | 2015 |
| HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial N Ahmed, V Brawley, M Hegde, K Bielamowicz, M Kalra, D Landi, ... JAMA oncology 3 (8), 1094-1101, 2017 | 704 | 2017 |
| Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape M Hegde, M Mukherjee, Z Grada, A Pignata, D Landi, SA Navai, ... The Journal of clinical investigation 126 (8), 3036-3052, 2016 | 632 | 2016 |
| TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy Z Grada, M Hegde, T Byrd, DR Shaffer, A Ghazi, VS Brawley, A Corder, ... Molecular Therapy-Nucleic Acids 2, 2013 | 513 | 2013 |
| HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors N Ahmed, VS Salsman, Y Kew, D Shaffer, S Powell, YJ Zhang, ... Clinical cancer research 16 (2), 474-485, 2010 | 401 | 2010 |
| Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma M Hegde, A Corder, KKH Chow, M Mukherjee, A Ashoori, Y Kew, ... Molecular Therapy 21 (11), 2087-2101, 2013 | 395 | 2013 |
| T cells redirected to EphA2 for the immunotherapy of glioblastoma KKH Chow, S Naik, S Kakarla, VS Brawley, DR Shaffer, Z Yi, N Rainusso, ... Molecular Therapy 21 (3), 629-637, 2013 | 269 | 2013 |
| Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression N Ahmed, VS Salsman, E Yvon, CU Louis, L Perlaky, WS Wels, ... Molecular Therapy 17 (10), 1779-1787, 2009 | 222 | 2009 |
| PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor Y Nakazawa, LE Huye, VS Salsman, AM Leen, N Ahmed, L Rollins, ... Molecular Therapy 19 (12), 2133-2143, 2011 | 162 | 2011 |
| TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer TT Byrd, K Fousek, A Pignata, C Szot, H Samaha, S Seaman, ... Cancer research 78 (2), 489-500, 2018 | 143 | 2018 |
| CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression K Fousek, J Watanabe, SK Joseph, A George, X An, TT Byrd, JS Morris, ... Leukemia 35 (1), 75-89, 2021 | 137 | 2021 |
| Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma M Hegde, SK Joseph, F Pashankar, C DeRenzo, K Sanber, S Navai, ... Nature communications 11 (1), 3549, 2020 | 117 | 2020 |
| Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma A Ghazi, A Ashoori, PJ Hanley, VS Brawley, DR Shaffer, Y Kew, ... Journal of immunotherapy 35 (2), 159-168, 2012 | 84 | 2012 |
| Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells D Liu, L Song, VS Brawley, N Robison, J Wei, X Gao, G Tian, A Margol, ... Clinical immunology 149 (1), 55-64, 2013 | 67 | 2013 |
| Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial. N Ahmed, V Brawley, M Hegde, K Bielamowicz, A Wakefield, A Ghazi, ... Journal for immunotherapy of cancer 3, 1-1, 2015 | 63 | 2015 |
| The miR-223/nuclear factor IA axis regulates glial precursor proliferation and tumorigenesis in the CNS SM Glasgow, D Laug, VS Brawley, Z Zhang, A Corder, Z Yin, STC Wong, ... Journal of Neuroscience 33 (33), 13560-13568, 2013 | 60 | 2013 |
| Abstract LB-147: Administration of HER2-CAR T cells after lymphodepletion safely improves T cell expansion and induces clinical responses in patients with advanced sarcomas SA Navai, C Derenzo, S Joseph, K Sanber, T Byrd, H Zhang, M Mata, ... Cancer Research 79 (13_Supplement), LB-147-LB-147, 2019 | 48 | 2019 |
| Expansion of HER2-CAR T cells after lymphodepletion and clinical responses in patients with advanced sarcoma. M Hegde, CC DeRenzo, H Zhang, M Mata, C Gerken, A Shree, Z Yi, ... Journal of Clinical Oncology 35 (15_suppl), 10508-10508, 2017 | 44 | 2017 |
| Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment VS Salsman, KKH Chow, DR Shaffer, H Kadikoy, XN Li, C Gerken, ... PloS one 6 (5), e20267, 2011 | 42 | 2011 |
| Glioma cells display complex cell surface topographies that resist the actions of cytolytic effector lymphocytes N Hoa, L Ge, Y Kuznetsov, A McPherson, AN Cornforth, JTH Pham, ... The Journal of Immunology 185 (8), 4793-4803, 2010 | 36 | 2010 |
